Healthcare Biocon receives DCGI nod for use of Itolizumab drug in moderate to severe COVID-19 patients Updated : July 13, 2020 04:52 PM IST Itolizumab is the first novel biologic therapy to be approved anywhere in the world for treating patients with moderate to severe COVID-19 complications, Itolizumab is now approved for the treatment of CRS in patients with moderate to severe ARDS due to COVID-19. Subscribe to Moneycontrol PRO at just Rs.33/- per month for the first year. Use code SUPERPRO. Limited period offer. Available on Web and Android.